Work

P-045 Idecabtagene Vicleucel (ide-cel) in Patients (pts) With Clinical High-Risk Early Relapse Multiple Myeloma (MM) Without Front-Line (1L) Autologous Stem Cell Transplantation (ASCT): KarMMA-2 Cohort 2B

Year: 2024

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(24)01948-7

Authors: Xavier Leleu, Alfred Chung, Noopur Raje, Meera Mohan, Reuben Benjamin, Adam Sperling, Larry Anderson, Madhav V. Dhodapkar, Shambavi Richard, Anna Truppel-Hartmann, Sarah Johnston, Fan Wu, Debashree Basudhar, Ethan Thompson, Devender Dhanda, Laurie Eliason, Sinhan Tran, Maria Chaudhry, Melissa Alsina

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4402735811

Cites:

Cited by: 4

Related to: 10